Social Capital Hedosophia Holdings IV (IPOD) and VI (IPOF) to Liquidate
by Nicholas Alan Clayton on 2022-09-20 at 7:39am

Social Capital IV (NYSE:IPOD) and Social Capital VI (NYSE:IPOF) each announced in 8-K filings this morning that they intend to not complete business combinations and will instead liquidate their trusts on October 17.

Both SPACs are led by serial sponsor and prominent SPAC advocate Chamath Palihapitiya, which makes the moves a telling sign of the difficulties inherent in getting a deal done in the current market. Shares for both SPACs will cease trading on October 14 and shareholders are expected to receive their pro rata share of the trust estimated at $10.01 per share by October 17.

Palihapitiya’s SPACs have completed six combinations since 2019, but, owing to their tech-heavy focus these de-SPACs have produced collective returns -48.1% as of the market’s last close. Many of these companies hit stunning highs in headier market days, like space tourism venture Virgin Galactic (NYSE:SPCE), which hit a high of $60.67 in February 2021 and SoFi (NASDAQ:SOFI), which hit $26.97 shortly after its January 2021 close. At least some of this market enthusiasm has been attributable to Palihapitiya’s large profile and popularity among retail investors.

Palihapitiya appeared on track to cover the full alphabet with his sequential SPAC tickers from IPOA to IPOZ and he even dipped into biotech with four SPACs listed with co-sponsor Suvretta Capital carrying tickers with the same inherently ambitious tickers DNAA, DNAB, DNAC, and DNAD. The first signs that momentum may have been shifting came as Social Capital Suvretta III saw 91.3% redemptions as it de-SPAC’d biopharm company ProKidney (NASDAQ:PROK) in July and Social Capital Suvretta I saw 99.1% redemptions a month later in closing with Akili (NASDAQ:AKLI).

The liquidation of IPOD and IPOF now puts some focus on DNAB and DNAD, which are the last remaining Palihapitiya-backed SPACs currently searching. They still have more time on their side with transaction deadlines not coming up until July 2023, which could well be enough time to complete transactions in a more favorable market. And, ProKidney is after all trading healthily above $10 despite the market slump.

Nonetheless, the liquidations appear to sound the end of an era with the current SPAC cycle coming to a grinding conclusion as a new one sets to begin in 2023.

 

Recent Posts
by Kristi Marvin on 2025-02-08 at 10:02am

Terms Tracker for the Week Ending February 7, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. This past week saw one new SPAC IPO price, bringing the year-to-date total to nine. K&F Growth Acquisition Corp. II successfully debuted and managed to...

by Nicholas Alan Clayton on 2025-02-07 at 2:43pm

Retail enthusiasm has been a lifeblood of many SPAC transactions through to the combined companies’ ongoing lives as public companies, and several have taken to buying up Bitcoin as a way of keeping sometimes fickle retail investors engaged. Enterprise software MicroStrategy (NASDAQ:MSTR) pioneered this tactic before spot Bitcoin ETFs were available to the general public....

by Nicholas Alan Clayton on 2025-02-07 at 8:23am

At the SPAC of Dawn  The markets may still be figuring out their way in careening the early decisions of the new presidential administration, but one de-SPAC decided to cash in on at least one of them yesterday. Rare earth miner Critical Metals (NASDAQ:CRML) raised $22.5 million in a private placement taking advantage of a...

by Nicholas Alan Clayton on 2025-02-06 at 8:15am

At the SPAC of Dawn  The market may have sighed in relief with the postponement of tariffs, but they may not have gone too far into the background as the US also reported a record high $98.4 billion trade deficit for December yesterday, which came in more than $2 billion deeper than expected. More signals...

by Nicholas Alan Clayton on 2025-02-05 at 8:23am

At the SPAC of Dawn  Commentators may still spar over the level of positive impact SPACs have had in some sectors, but Peter Beck, CEO of Rocket Lab (NASDAQ:RKLB), believes the vehicles have been particularly positive for the space industry. Although he described the period as a “crazy, crazy time” when speaking at the Smallsat...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved